MedTrace Logo

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

NCT02437786 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2018-01-17

No results posted yet for this study

Summary

The specific clinical trial is a part in which ALK- Abelló will directly work to explore human immunological mechanisms of SIT (observed after GRAZAX treatment).

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

DRUG

GRAZAX

GRAZAX

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • CARLOS BLANCO, PhD · HOSPITAL UNIVERSITARIO DE LA PRINCESA MADRID

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437786 on ClinicalTrials.gov